This is a randomized, controlled, phase 2 study to assess the efficacy and safety of ablation
followed by tislelizumab versus ablation alone in patients with early recurrent
Ablation is one of the main treatments for early recurrent HCC, and its immune stimulation is
expected to improve the efficacy of anti-PD-1 immune checkpoint inhibitor therapy.
Tislelizumab is a new immunotherapy agent with independent intellectual property rights in
China, which is highly efficient and safe. It is of great value to combine Tislelizumab with
ablation to reduce the risk of recurrence in HCC patients. In this study, early-stage HCC
patients with high risk of recurrence would be included and randomly assigned to receive
ablation plus Tislelizumab or ablation alone. The tumor recurrence, overall survival and
safety would be observed and recorded to analyze whether Tislelizumab can reduce the
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.